Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met
Psyence BioMed completed its additional US$2.6M investment in related party PsyLabs after both backstop milestones were achieved ahead of the December 31 deadline, lifting its stake from about 41.13% to 43.37%. The milestones comprised completion of an ibogaine regulatory readiness documentation package and execution of a U.S. cGMP manufacturing agreement with DEA-registered Benuvia, signed by the company's Texas subsidiary TIRC.
Key figures
- Deal Value Usd
- 2599896
- Share price
- 2564
- Total commitment
- $5 million
- Shares subscribed
- 1014
- Pre money valuation
- $54 million
- Psy Labs ownership after
- 43.37%
- Psy Labs ownership before
- 41.13%
- Definitive agreement deadline
- November 30, 2026
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.